VYNE News and Press, VYNE Therapeutics Inc Com From 05/06/21

Shares of VYNE Therapeutics (NASDAQ: VYNE) were crashing 18.1% lower as of 11:35 a.m. EDT on Thursday. The big decline came after the company announced its first-quarter results before the market opened. VYNE reported Q1 revenue of $4.1 million, up from $1.8 million in the prior...

Gainers: Stealth BioTherapeutics (MITO) +45%, Biofrontera (BFRA) +18%, BioCryst Pharmaceuticals (BCRX) +15%, Orgenesis (ORGS) +12%, GT Biopharma (GTBP) +4%.Losers: Regional Health Properties (RHE) -24%, VYNE Therapeutics (VYNE) ...

James River Group Holdings (JRVR) -23% after stock offering and Q1 earnings release.Fastly (FSLY) -19% on Q1 earnings release.Regional Health Properties (RHE) -15%.Rocket Companies (RKT) -13% on Q1 earnings release.Etsy (ETSY) -11% on Q1 earnings releas...

VYNE Therapeutics (VYNE): Q1 Non-GAAP EPS of -$0.37 beats by $0.03; GAAP EPS of -$0.42 beats by $0.06.Revenue of $4.12M (+135.4% Y/Y) misses by $0.65M.Press Release For further details see: VYNE Therapeutics EPS beats by $0.03, misses on revenue

BRIDGEWATER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the first quarter ended March 31, 2021, on Thursday, May 6, 2021, before the market...

Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) traded today at $4.71, breaking its 52-week low. Approximately 8.5 million shares have changed hands today, as compared to an average 30-day volume of 874,000 shares. In the past 52 weeks, VYNE Therapeutics Inc. share prices are bracketed by...

VYNE Therapeutics Inc. (NASDAQ:VYNE) traded today at a new 52-week low of $4.80. Approximately 8.5 million shares have changed hands today, as compared to an average 30-day volume of 877,000 shares. VYNE Therapeutics Inc. has overhead space with shares priced $4.80, or 12.7% below the av...

VYNE has two approved products and a late-stage asset. The company has adequate cash after the recent offering. The company is a leader in the acne and rosacea markets. For further details see: VYNE Therapeutics: Rapidly Progressing In The Dermatology Market

Innovation, R&D and an aging population are long-term secular trends that will provide a tailwind to the biotechnology sector. The Insurgent AI Deep Innovation Model uses Deep Learning and secular tailwinds to generate alpha. Evaluating investment strategies is challenging, es...

The following slide deck was published by VYNE Therapeutics Inc. in conjunction with this event. For further details see: VYNE Therapeutics (VYNE) Investor Presentation - Slideshow